LOS ANGELES (Reuters) – Women face a myriad of complications during pregnancy, including an umbilical cord infection. For this, experts from the University of California, Los Angeles (UCLA) have developed a nanoavial that can be useful in the treatment of a disease called ‘placenta echrita spectrum disorder’.
This condition associated with the placenta can be fatal. In it, the placenta attaches so deeply to the walls of the uterus that it does not separate even after the baby is born. This causes more bleeding during pregnancy. If the mother is not taken care of at this time, it can lead to her death. But it is a rare condition and occurs in only half a percent of mothers.
Prior to this, the diagnosis of placenta accreta spectrum disorder is based on the patient’s medical history and ultrasound. Medical history has shown caesarean section and umbilical cord condition while it is confirmed by ultrasound.
In this regard, a blood test has been developed which can be very useful for dangerous pregnancy conditions. It has been tested on more than 100 pregnant women and with 79% accuracy it has identified Placenta accreta, while 93% of women have reported negative (ie no disease). This is undoubtedly an important achievement.
Yalda Afsher of UCLA said that in this way we can not only better treat the problems associated with the placenta but also help to save the lives of mothers and children. But all this is possible thanks to a modern device called the nano velcro chip.
UCLA professors Yazin Zhou and Xian Rongsing have been working on it for the past 15 years. It was originally designed to detect cancerous tumors or cells but has now undergone some modifications. It has been given the size of a doctrine stamp in which a thousand degrees thinner than a human hair has been applied. All of these hairs are treated with antibodies that recognize specific cells.
This chip can detect infected cells in the placenta. The cells of the placenta accreta are called trophoblasts and begin to form within a few days of conception. The blood sample that is placed on the chip identifies the trophoblast.
As soon as the disease is identified, doctors can take better care of the patient and try to save him from the disease.